NEW YORK, October 20, 2025 – Hologic Inc. (HOLX) shares jumped 4.5% Monday after reports that Blackstone Inc. and TPG Inc. are in advanced talks to acquire the medical device maker for more than 17 billion.
The potential deal would represent one of the largest private equity healthcare acquisitions this year, giving investors exposure to Hologic’s dominant position in women’s health diagnostics and breast cancer screening technology.
- Blackstone, TPG eye 17 billion Hologic acquisition deal
- Stock surges 4.5% on takeover speculation Monday
- Deal includes debt, values company above current market cap
Market Reaction & Context
Hologic shares rose to 73.00 in Monday trading, building on Friday’s 2% gain to 69.85 1. The stock had surged 6% in after-hours trading Friday following initial reports of the takeover discussions 2.
The company’s current market capitalization stands at approximately 15.5 billion, meaning the reported 17 billion enterprise value includes the assumption of debt 3. Hologic has outperformed the broader healthcare sector this year, with shares up roughly 12% compared to the S&P 500 Health Care Select Sector SPDR Fund’s 8% gain.
Deal Structure & Background
Bloomberg reported that the private equity firms are in advanced discussions to acquire the Marlborough, Massachusetts-based company, citing people familiar with the matter 4. The negotiations represent a revival of interest from Blackstone and TPG, which previously explored a takeover of Hologic in September.
According to reports, Hologic had previously rejected a 16 billion offer from the consortium 5. The current discussions suggest the private equity firms have increased their valuation to secure a deal.
Company Profile & Strategic Value
Hologic specializes in medical diagnostics and surgical products focused on women’s health, including mammography systems, cervical cancer screening tests, and molecular diagnostics. The company has built a strong competitive moat in breast cancer detection through its 3D mammography technology.
The potential acquisition comes amid a broader surge in healthcare deals, as private equity firms seek to capitalize on stable cash flows and demographic trends driving demand for medical devices and diagnostics 6. Hologic’s recurring revenue from consumables and service contracts makes it an attractive target for leveraged buyout firms.
Market Implications
If completed, the transaction would rank among the largest private equity healthcare deals of 2025. The timing reflects private equity’s renewed appetite for healthcare assets after a slowdown in deal activity over the past two years due to higher interest rates and financing costs.
For Hologic shareholders, the reported valuation represents a significant premium to recent trading levels. The company’s stock had traded in a range of 60-75 over the past 12 months before Monday’s surge.
Outlook
No official confirmation has been provided by Hologic, Blackstone, or TPG regarding the reported discussions. The companies typically do not comment on market speculation until formal agreements are reached.
The deal’s completion would depend on due diligence, financing arrangements, and regulatory approvals. Given Hologic’s position in the medical device sector, antitrust review would be expected but likely routine.
Not investment advice. For informational purposes only.
References
1Mackenzie Tatananni. “Hologic Stock Rises as Report Says Blackstone and TPG in Advanced Takeover Talks”. Barron’s. Retrieved October 20, 2025.
2“Hologic stock rises after report of potential Blackstone, TPG takeover”. Investing.com. Retrieved October 20, 2025.
3“Blackstone and TPG poised for 17bn move on Hologic amid healthcare deal surge”. PE Insights. Retrieved October 20, 2025.
4“Hologic (HOLX) Nears Acquisition Deal With Blackstone and TPG”. GuruFocus. Retrieved October 20, 2025.
5“Blackstone, TPG near 17B Hologic deal (HOLX:NASDAQ)”. Seeking Alpha. Retrieved October 20, 2025.
6“Blackstone, TPG Near Hologic Deal for More Than 17 Billion”. Bloomberg Law. Retrieved October 20, 2025.